It has been demonstrated that targeting CD33 with lintuzumab antibody radiolabeled with 225Ac has promising activity in patients with relapsed/refractory AML in phase 1/2 clinical trials [5,6,7]. This evidence concerns the gene CD33 and acute myeloid leukemia.